Paraytec is pioneering the use of UV light detection to measure protein aggregation in biopharmaceuticals and is part of an Innovate UK funded R&D project (NEXUS) that includes Malvern Panalytical, the University of Central Lancashire, GSK, Medimmune and Fujifilm Diosynth.
Aggregates are an impurity that must be controlled and must stay within product specifications, so measurement is essential to ensure they meet the requirements of regulatory agencies said Braveheartm which has updated on the other constituents of its portfolio of six core companies.
Plant nutrients firm Pharm 2 Farm (Braveheart 33.33%) is bidding to get some of the £90mln Innovate UK grant funding available to help agritech businesses.
Biotechnology company Kirkstall (64.67%) is involved with the €4.7 million Horizon 2020 project developing techniques to grow human organs by using light to modify the growth of cells.
Kirkstall is providing specialist Quasi-Vivo products in which the cell cultures will be grown.
Gyrometric Systems (19.95%) has developed shaft monitoring and measurement systems for revolutions as low as 0.25 revolutions per minute, which is useful for wind turbines.
Its ship drive monitoring systems, meanwhile, will be exhibited next year in September at SMM Hamburg, the world's largest exhibition for ship technology.
Phasefocus Holdings (21.20%) ha recently been granted a new US patent for a fundamental improvement in its underlying ptychography imaging technology.
The method protected by the new patent has the potential to speed up Phasefocus's systems by a factor of 10 times.
Sentinel Medical (38.40%) is to revise the trial protocols for its prototype instrument to detect bladder cancer from urine after initial work at Sheffield University.